55 results
Search Results
2. Urolithin A Hijacks ERK1/2‐ULK1 Cascade to Improve CD8+ T Cell Fitness for Antitumor Immunity.
- Author
-
Ma, Shuaiya, Wu, Qi, Wu, Wenxian, Tian, Ye, Zhang, Jie, Chen, Chaojia, Sheng, Xue, Zhao, Fangcheng, Ding, Lu, Wang, Taixia, Zhao, Laixi, Xie, Yuying, Wang, Yongxiang, Yue, Xuetian, Wu, Zhuanchang, Wei, Jian, Zhang, Kun, Liang, Xiaohong, Gao, Lifen, and Wang, Hongyan
- Subjects
T cells ,CYTOTOXIC T cells ,CHIMERIC antigen receptors ,REACTIVE oxygen species ,IMMUNITY ,CD8 antigen ,OXYGEN consumption - Abstract
According to the latest evidence, the microbial metabolite Urolithin A (UA), known for its role in promoting cellular health, modulates CD8+ T cell‐mediated antitumor activity. However, the direct target protein of UA and its underlying mechanism remains unclear. Here, this research identifies ERK1/2 as the specific target crucial for UA‐mediated CD8+ T cell activation. Even at low doses, UA markedly enhances the persistence and effector functions of primary CD8+ cytotoxic T lymphocytes (CTLs) and human chimeric antigen receptor (CAR) T cells both in vitro and in vivo. Mechanistically, UA interacts directly with ERK1/2 kinases, enhancing their activation and subsequently facilitating T cell activation by engaging ULK1. The UA‐ERK1/2‐ULK1 axis promotes autophagic flux in CD8+ CTLs, enhancing cellular metabolism and maintaining reactive oxygen species (ROS) levels, as evidenced by increased oxygen consumption and extracellular acidification rates. UA‐treated CD8+ CTLs also display elevated ATP levels and enhanced spare respiratory capacity. Overall, UA activates ERK1/2, inducing autophagy and metabolic adaptation, showcasing its potential in tumor immunotherapy and interventions for diseases involving ERKs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Hybrid Ginseng‐derived Extracellular Vesicles‐Like Particles with Autologous Tumor Cell Membrane for Personalized Vaccination to Inhibit Tumor Recurrence and Metastasis.
- Author
-
Wang, Haoran, Mu, Jiankang, Chen, Yexing, Liu, Yali, Li, Xianghui, Li, Hao, and Cao, Peng
- Subjects
CANCER relapse ,METASTASIS ,DISEASE relapse ,CYTOTOXIC T cells ,CANCER vaccines - Abstract
Personalized cancer vaccines based on resected tumors from patients is promising to address tumor heterogeneity to inhibit tumor recurrence or metastasis. However, it remains challenge to elicit immune activation due to the weak immunogenicity of autologous tumor antigens. Here, a hybrid membrane cancer vaccine is successfully constructed by membrane fusion to enhance adaptive immune response and amplify personalized immunotherapy, which formed a codelivery system for autologous tumor antigens and immune adjuvants. Briefly, the functional hybrid vesicles (HM‐NPs) are formed by hybridizing ginseng‐derived extracellular vesicles‐like particles (G‐EVLPs) with the membrane originated from the resected autologous tumors. The introduction of G‐EVLPs can enhance the phagocytosis of autologous tumor antigens by dendritic cells (DCs) and facilitate DCs maturation through TLR4, ultimately activating tumor‐specific cytotoxic T lymphocytes (CTLs). HM‐NPs can indeed strengthen specific immune responses to suppress tumors recurrence and metastasis including subcutaneous tumors and orthotopic tumors. Furthermore, a long‐term immune protection can be obtained after vaccinating with HM‐NPs, and prolonging the survival of animals. Overall, this personalized hybrid autologous tumor vaccine based on G‐EVLPs provides the possibility of mitigating tumor recurrence and metastasis after surgery while maintaining good biocompatibility. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Single‐cell transcriptomic landscape reveals distinct tumourigenesis and immune microenvironments in secondary radiation‐exposed rectal cancer.
- Author
-
Guan, Xu, Bi, Xiaoman, Wei, Ran, Zhao, Zhixun, Lu, Zhao, Jiang, Zheng, Wang, Xishan, and Wu, Deng
- Subjects
KILLER cells ,MYELOID cells ,CYTOTOXIC T cells ,REGULATORY T cells ,MEDICAL sciences ,RECTAL cancer ,ANGIOSARCOMA - Abstract
This article explores the molecular characteristics and immune microenvironments of secondary radiation-exposed rectal cancers (SRCs) compared to primary rectal cancers (PRCs). The study used single-cell transcriptomic sequencing to analyze the cell type-specific profiles of 18 SRCs and identified distinct differences in copy number variation and immune cell composition between SRCs and PRCs. The findings suggest that oncogene amplification and the activation of Treg cells may promote the progression of SRCs, while the emergence of neutrophils and activation of macrophages contribute to the immune microenvironment of SRCs. The study provides valuable insights into the tumorigenesis of SRCs and potential therapeutic strategies. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
5. Protein Kinase STK24 Promotes Tumor Immune Evasion via the AKT‐PD‐L1 Axis.
- Author
-
Wang, Ning, Jiang, Yu, Li, Mengjie, Wang, Haofei, Pan, Jie, Tang, Yang, Xie, Shaofang, Xu, Yunyang, Li, Xu, Zhou, Xuefei, Xu, Pinglong, Lin, Wenlong, and Wang, Xiaojian
- Subjects
PROTEIN kinases ,CYTOTOXIC T cells ,KILLER cells ,TUMOR growth ,T cells - Abstract
Immunotherapy targeting PD‐L1 is still ineffective for a wide variety of tumors with high unpredictability. Deploying combined immunotherapy with alternative targeting is practical to overcome this therapeutic resistance. Here, the deficiency of serine‐threonine kinase STK24 is observed in tumor cells causing substantial attenuation of tumor growth in murine syngeneic models, a process relying on cytotoxic CD8+ T and NK cells. Mechanistically, STK24 in tumor cells associates with and directly phosphorylates AKT at Thr21, which promotes AKT activation and subsequent PD‐L1 induction. Deletion or inhibition of STK24, by contrast, blocks IFN‐γ‐mediated PD‐L1 expression. Various murine models indicate that in vivo silencing of STK24 can significantly enhance the efficacy of the anti‐PD‐1 blockade strategy. Elevated STK24 levels are observed in patient specimens in multiple tumor types and inversely correlated with intratumoral infiltration of cytotoxic CD8+ T cells and with patient survival. The study collectively identifies STK24 as a critical modulator of antitumor immunity, which engages in AKT and PD‐L1/PD‐1 signaling and is a promising target for combined immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Dissecting the immune discrepancies in mouse liver allograft tolerance and heart/kidney allograft rejection.
- Subjects
GRAFT rejection ,KIDNEYS ,HEART ,CYTOTOXIC T cells ,HOMOGRAFTS ,LIVER transplantation ,MYELOID cells ,INSULIN receptors - Abstract
The liver is the most tolerogenic of transplanted organs. However, the mechanisms underlying liver transplant tolerance are not well understood. The comparison between liver transplantation tolerance and heart/kidney transplantation rejection will deepen our understanding of tolerance and rejection in solid organs. Here, we built a mouse model of liver, heart and kidney allograft and performed single-cell RNA sequencing of 66,393 cells to describe the cell composition and immune cell interactions at the early stage of tolerance or rejection. We also performed bulk RNA-seq of mouse liver allografts from Day 7 to Day 60 posttransplantation to map the dynamic transcriptional variation in spontaneous tolerance. The transcriptome of lymphocytes and myeloid cells were characterized and compared in three types of organ allografts. Cell-cell interaction networks reveal the coordinated function of Kupffer cells, macrophages and their associated metabolic processes, including insulin receptor signalling and oxidative phosphorylation in tolerance induction. Cd11b+ dendritic cells (DCs) in liver allografts were found to inhibit cytotoxic T cells by secreting anti-inflammatory cytokines such as Il10. In summary, we profiled single-cell transcriptome analysis of mouse solid organ allografts. We characterized the immune microenvironment of mouse organ allografts in the acute rejection state (heart, kidney) and tolerance state (liver). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Impact of inflammation and the immune system on hepatocellular carcinoma recurrence after hepatectomy.
- Author
-
She, Sha, Shi, Jinzhi, Zhu, Jiling, Yang, Fan, Yu, Jia, and Dai, Kai
- Subjects
CYTOTOXIC T cells ,IMMUNOREGULATION ,PLATELET lymphocyte ratio ,REGULATORY T cells ,HEPATECTOMY ,IMMUNOTHERAPY ,HEPATOCELLULAR carcinoma - Abstract
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer‐related death worldwide. Hepatectomy remains the first‐line treatment for patients with resectable HCC. However, the reported recurrence rate of HCC at 5 years after surgery is between 50% and 70%. Tumor‐related factors, including tumor size, number and differentiation, and underlying liver disease are well‐known risk factors for recurrence after treatment. In addition to tumor‐related factors, ever‐increasing amounts of studies are finding that the tumor microenvironment also plays an important role in the recurrence of HCC, including systemic inflammatory response and immune regulation. Based on this, some inflammatory and immune markers were used in predicting postoperative cancer recurrence. These include neutrophil‐to‐lymphocyte ratio, platelet‐to‐lymphocyte ratio, cytotoxic T cells, and regulatory T cells, among others. In this review, we summarized the inflammatory and immune markers that affect recurrence after HCC resection in order to provide direction for adjuvant therapy after HCC resection and ultimately achieve the goal of reducing recurrence. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Near‐Infrared‐II Nanoparticles for Vascular Normalization Combined with Immune Checkpoint Blockade via Photodynamic Immunotherapy Inhibit Uveal Melanoma Growth and Metastasis.
- Author
-
Zheng, Xiaoqin, Shi, Yunyi, Tang, Dongsheng, Xiao, Haihua, Shang, Kun, Zhou, Xuezhi, and Tan, Gang
- Subjects
PROGRAMMED cell death 1 receptors ,CYTOTOXIC T cells ,NANOMEDICINE ,IMMUNE checkpoint proteins ,REACTIVE oxygen species ,FLUORESCENT polymers ,PHOTODYNAMIC therapy ,TUMOR treatment - Abstract
Photodynamic therapy (PDT) has been widely employed in tumor treatment due to its effectiveness. However, the tumor hypoxic microenvironment which is caused by abnormal vasculature severely limits the efficacy of PDT. Furthermore, the abnormal vasculature has been implicated in the failure of immunotherapy. In this study, a novel nanoparticle denoted as Combo‐NP is introduced, composed of a biodegradable NIR II fluorescent pseudo‐conjugate polymer featuring disulfide bonds within its main chain, designated as TPA‐BD, and the vascular inhibitor Lenvatinib. Combo‐NP exhibits dual functionality by not only inducing cytotoxic reactive oxygen species (ROS) to directly eliminate tumor cells but also eliciting immunogenic cell death (ICD). This ICD response, in turn, initiates a robust cascade of immune reactions, thereby augmenting the generation of cytotoxic T lymphocytes (CTLs). In addition, Combo‐NP addresses the issue of tumor hypoxia by normalizing the tumor vasculature. This normalization process enhances the efficacy of PDT while concurrently fostering increased CTLs infiltration within the tumor microenvironment. These synergistic effects synergize to potentiate the photodynamic‐immunotherapeutic properties of the nanoparticles. Furthermore, when combined with anti‐programmed death‐ligand 1 (PD‐L1), they showcase notable inhibitory effects on tumor metastasis. The findings in this study introduce an innovative nanomedicine strategy aimed at triggering systemic anti‐tumor immune responses for the treatment of Uveal melanoma. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Induction of contact-dependent CD8+ regulatory T cells through stimulation with staphylococcal and streptococcal superantigens.
- Author
-
Taylor, Amanda L., Cross, Elizabeth L. A., and Llewelyn, Martin J.
- Subjects
STAPHYLOCOCCAL disease treatment ,CYTOTOXIC T cells ,GENETIC regulation ,SUPERANTIGENS ,TOXIC shock syndrome ,CELL proliferation ,BIOMARKERS - Abstract
Summary The bacterial superantigen exotoxins of Staphylococcus aureus and Streptococcus pyogenes are potent stimulators of polyclonal T-cell proliferation. They are the causes of toxic shock syndrome but also induce CD25
+ FOXP3+ regulatory cells in the CD4 compartment. Several studies have recently described different forms of antigen-induced regulatory CD8+ T cells in the context of inflammatory diseases and chronic viral infections. In this paper we show that bacterial superantigens are potent inducers of human regulatory CD8+ T cells. We used four prototypic superantigens of S. aureus (toxic shock syndrome toxin-1 and staphylococcal enterotoxin A) and Str. pyogenes (streptococcal pyrogenic exotoxins A and K/L). At concentrations below 1 ng/ml each toxin triggers concentration-dependent T-cell receptor Vβ-specific expression of CD25 and FOXP3 on CD8+ T cells. This effect is independent of CD4+ T-cell help but requires antigen-presenting cells for maximum effect. The cells also express the activation/regulatory markers cytotoxic T-lymphocyte antigen-4 and glucocorticoid-induced tumour necrosis factor receptor-related protein and skin homing adhesins CD103 and cutaneous lymphocyte-associated antigen. Superantigen-induced CD25+ FOXP3+ CD8+ T cells were as potent as freshly prepared naturally occurring CD4+ regulatory T cells in suppressing proliferation of CD4+ CD25− T cells in response to anti-CD3 stimulation. Although superantigen-induced CD8+ CD25+ FOXP3+ express interleukin-10 and interferon-γ their suppressive function is cell contact dependent. Our findings indicate that regulatory CD8+ T cells may be a feature of acute bacterial infections contributing to immune evasion by the microbe and disease pathogenesis. The presence and magnitude of regulatory CD8+ T-cell responses may represent a novel biomarker in such infections. Superantigen-induced regulatory CD8+ T cells also have therapeutic potential. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
10. T‐cell derived extracellular vesicles prime macrophages for improved STING based cancer immunotherapy.
- Author
-
Hansen, Aida S., Jensen, Lea S., Gammelgaard, Kristine R., Ryttersgaard, Kristoffer G., Krapp, Christian, Just, Jesper, Jønsson, Kasper L., Jensen, Pia B., Boesen, Thomas, Johansen, Mogens, Etzerodt, Anders, Deleuran, Bent W., and Jakobsen, Martin R.
- Subjects
EXTRACELLULAR vesicles ,TYPE I interferons ,MACROPHAGES ,IMMUNOTHERAPY ,TUMOR microenvironment ,T cells ,CYTOTOXIC T cells - Abstract
A key phenomenon in cancer is the establishment of a highly immunosuppressive tumour microenvironment (TME). Despite advances in immunotherapy, where the purpose is to induce tumour recognition and hence hereof tumour eradication, the majority of patients applicable for such treatment still fail to respond. It has been suggested that high immunological activity in the tumour is essential for achieving effective response to immunotherapy, which therefore have led to exploration of strategies that triggers inflammatory pathways. Here activation of the stimulator of interferon genes (STING) signalling pathway has been considered an attractive target, as it is a potent trigger of pro‐inflammatory cytokines and types I and III interferons. However, immunotherapy combined with targeted STING agonists has not yielded sustained clinical remission in humans. This suggests a need for exploring novel adjuvants to improve the innate immunological efficacy. Here, we demonstrate that extracellular vesicles (EVs), derived from activated CD4+ T cells (T‐EVs), sensitizes macrophages to elevate STING activation, mediated by IFNγ carried on the T‐EVs. Our work support that T‐EVs can disrupt the immune suppressive environment in the tumour by reprogramming macrophages to a pro‐inflammatory phenotype, and priming them for a robust immune response towards STING activation. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
11. Immune responses to citrullinated and homocitrullinated peptides in healthy donors are not restricted to the HLA SE shared allele and can be selected into the memory pool.
- Author
-
Choudhury, Ruhul H., Daniels, Ian, Vaghela, Poonam, Atabani, Suha, Kirk, Thomas, Symonds, Peter, Cook, Katherine W., Al‐Omari, Abdullah, Weston, Daisy, Shah, Sabaria, Hutchinson, David, Paston, Samantha J., Metheringham, Rachael L., Brentville, Victoria A., and Durrant, Lindy G.
- Subjects
MONONUCLEAR leukocytes ,CYTOTOXIC T cells ,LYMPHOBLASTOID cell lines ,T cell receptors ,IMMUNE response ,CELLULAR recognition ,HISTOCOMPATIBILITY antigens - Abstract
Citrullination and homocitrullination are stress induced post‐translational modifications (siPTMs) which can be recognized by T cells. Peripheral blood mononuclear cells isolated from healthy donors and rheumatoid arthritis (RA) patients were stimulated with nine siPTM‐peptides. CD45RA/CD45RO depletion was employed to determine if peptide‐specific responses are naïve or memory. Human leucocyte antigen (HLA)‐DP4 and HLA‐DR4 transgenic mice were immunized with siPTM‐peptides and immune responses were determined with ex vivo ELISpot assays. The majority (24 out of 25) of healthy donors showed CD4 T cell‐specific proliferation to at least 1 siPTM‐peptide, 19 to 2 siPTM‐peptides, 14 to 3 siPTM‐peptides, 9 to 4 siPTM‐peptides, 6 to 5 siPTM‐peptides and 4 to 6 siPTM‐peptides. More donors responded to Vim28‐49cit (68%) and Bip189‐208cit (75%) compared with Vim415‐433cit (33%). In RA patients, the presentation of citrullinated epitopes is associated with HLA‐SE alleles; however, we witnessed responses in healthy donors who did not express the SE allele. The majority of responding T cells were effector memory cells with a Th1/cytotoxic phenotype. Responses to Vim28‐49cit and Eno241‐260cit originated in the memory pool, while the response to Vim415‐433cit was naïve. In the HLA‐DP4 and HLA‐DR4 transgenic models, Vim28cit generated a memory response. Peptide‐specific T cells were capable of Epstein–Barr virus transformed lymphoblastoid cell line recognition suggesting a link with stress due to infection. These results suggest siPTM‐peptides are presented under conditions of cellular stress and inflammation and drive cytotoxic CD4 T cell responses that aid in the removal of stressed cells. The presentation of such siPTM‐peptides is not restricted to HLA‐SE in both humans and animal models. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
12. Featured Abstract.
- Subjects
PROGRAMMED cell death 1 receptors ,WOUND healing ,CYTOTOXIC T cells ,LIFE sciences ,MEDICAL sciences ,MOLECULAR biology ,MORPHOLOGY ,CYTOLOGY - Abstract
PF13: EV Heterogeneity 1 Chairs: Michael Harding, Andre Gorgens Location: Hall 4A 16:00 - 18:00 PF13.08 Comparisons of Tetraspanin profile of Extracellular Vesicles-derived from Sarcoma Cel... Thitikan Jirakittisonthon SP 1 sp ; Orman L. Snyder SP 2 sp ; Hong He SP 3 sp ; Mark Weiss SP 1 sp I SP 1 sp Kansas State University, Manhattan, USA; SP 2 sp Kansas State University, Topeka, USA; SP 3 sp Kansas State University, USA i B Introduction b : Based on Minimum Information for Studies of Extracellular Vesicles 2018 (MISEV 2018), characterization of EVs using transmembrane protein markers is one of the criteria for characterization. B Funding b : Funding was partly provided by NIH grants DP1DK126199, and DP2 EB028110-01 awarded to DGP B keywords b : Engineered EVs, immunomodulation, solid tumors, nonviral gene delivery, tissue nanotransfection PT17.13 Isolation of neuron-derived extracellular vesicles from biological fluids for the dia... Igor V. Kurochkin; Lausonia Ramaswamy I Sysmex Co., Kobe, Japan i B Introduction b : The molecular content of extracellular vesicles (EVs) largely reflects the content of cells of origin and thus analysis of neuron-derived EVs (NDEs) present in plasma offers a possibility of minimally invasive diagnosis of neurological disorders. B keywords b : Extracellular vesicles (EVs), MicroRNAs, Nonalcoholic fatty liver disease, Lipotoxicity, PT09: EVs from Microorganism 1 Chairs: Meta Kuehn, Irma Schabussova Location: Hall 4A 16:45 - 18:45 PT09.14 Examining the role of bacterial extracellular vesicles in host blood pressure regulat... Feiya Shi SP 1 sp ; Rishi Wagle SP 1 sp ; Sriram Ayyaswamy SP 1 sp ; DAVID DURGAN SP 2 sp I SP 1 sp Baylor College of Medicine, USA; SP 2 sp Baylor College of Medicine, Houston, USA i B Introduction b : We have previously demonstrated that disruption of the normal gut microbiota composition, termed gut dysbiosis, is an underlying cause of hypertension (HT). [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
13. PD1hi CD200hi CD4+ exhausted T cell increase immunotherapy resistance and tumour progression by promoting epithelial–mesenchymal transition in bladder cancer.
- Author
-
Wu, Chun, Duan, Lianhui, Li, Hongmu, Liu, Xuefei, Cai, Taonong, Yang, Yang, Yin, Yuting, Chang, Wuguang, Zhong, Leqi, Zhang, Lin, Cheng, Yixin, Qin, Haide, Wen, Zhesheng, Wang, Huiyun, and Mai, Shijuan
- Subjects
EPITHELIAL-mesenchymal transition ,BLADDER cancer ,IMMUNE checkpoint inhibitors ,PROGRAMMED cell death 1 receptors ,IMMUNOTHERAPY ,CANCER cells ,T cells ,CYTOTOXIC T cells - Abstract
Background: Bladder cancer (BLCA) is one of the most diagnosed cancers in humans worldwide. Recently, immunotherapy has become a main treatment option for BC. However, most BLCA patients do not respond to immune checkpoint inhibitors or relapse after immunotherapy. Therefore, it is very important to identify novel biomarkers for the prediction of immunotherapy response in B patients. Methods: Pancancer single‐cell RNA sequencing (scRNA‐seq) data were used to identify the clusters of CD4+ T cells in the tumour microenvironment (TME). The clinical significance of key CD4+ T‐cell clusters was evaluated based on the survival data of two independent immunotherapy bladder cancer (BLCA) cohorts. We also investigated the function of key clusters of CD4+ T cell in the TME of BC cells in vitro. Results: This study identified two novel exhausted CD4+ T‐cell subpopulations with the expression of PD1hi CD200hi or PD1hi CD200low in BC patients. Moreover, BLCA patients with a high level of PD1hi CD200hi CD4+ exhausted T cell showed immunotherapy resistance. Cell function analysis demonstrated that PD1hi CD200hi CD4+ exhausted T cell can promote epithelial–mesenchymal transition (EMT) and angiogenesis in BLCA cells. In addition, PD1hi CD200hi CD4+ exhausted T cells were shown to communicate with malignant BLCA cells through the GAS6–AXL axis. Finally, we also found that GAS6 expression is upregulated in B cells by METTL3‐mediated m6A modification. Conclusions: PD1hi CD200hi CD4+ exhausted T cell may serve as a novel biomarker for poor prognosis and immunotherapy resistance in B. Targeted inhibitors of PD1hi CD200hi CD4+ exhausted T cells may help improve the efficacy of immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. Anti-tumour activity and store operated calcium entry: new roles in immunology.
- Author
-
Singh, Kavisha and Rosenberg, Paul
- Published
- 2013
- Full Text
- View/download PDF
15. The therapeutic mavericks: Potent immunomodulating chaperones capable of treating human diseases.
- Author
-
Eggleton, Paul, De Alba, Jorge, Weinreich, Michael, Calias, Perry, Foulkes, Roly, and Corrigall, Valerie M.
- Subjects
ENDOPLASMIC reticulum ,UNFOLDED protein response ,CYTOTOXIC T cells ,REGULATORY T cells ,SLEEP deprivation ,CANCER cells ,CELL membranes - Abstract
Two major chaperones, calreticulin (CRT) and binding immunoglobulin protein (GRP78/BiP) dependent on their location, have immunoregulatory or anti‐inflammatory functions respectively. CRT induces pro‐inflammatory cytokines, dendritic cell (DC) maturation and activates cytotoxic T cells against tumours. By contrast, GRP78/BiP induces anti‐inflammatory cytokines, inhibits DC maturation and heightens T‐regulatory cell responses. These latter functions rebalance immune homeostasis in inflammatory diseases, such as rheumatoid arthritis. Both chaperones are therapeutically relevant agents acting primarily on monocytes/DCs. Endogenous exposure of CRT on cancer cell surfaces acts as an 'eat‐me' signal and facilitates improved elimination of stressed and dying tumour cells by DCs. Therefore, therapeutics that promote endogenous CRT translocation to the cell surface can improve the removal of cancer cells. However, infused recombinant CRT dampens this cancer cell eradication by binding directly to the DCs. Low levels of endogenous BiP appear as a surface biomarker of endoplasmic reticulum (ER) stress in some types of tumour cells, a reflection of cells undergoing proliferation, in which resulting hypoxia and nutrient deprivation perturb ER homeostasis triggering the unfolded protein response, leading to increased expression of GRP78/BiP and altered cellular location. Conversely, infusion of an analogue of GRP78/BiP (IRL201805) can lead to long‐term immune resetting and restoration of immune homeostasis. The therapeutic potential of both chaperones relies on them being relocated from their intracellular ER environment. Ongoing clinical trials are employing therapeutic interventions to either enhance endogenous cell surface CRT or infuse IRL201805, thereby triggering several disease‐relevant immune responses leading to a beneficial clinical outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. Interdependence of sequential cytotoxic T lymphocyte and natural killer cell cytotoxicity against melanoma cells.
- Author
-
Friedmann, Kim S., Kaschek, Lea, Knörck, Arne, Cappello, Sabrina, Lünsmann, Niklas, Küchler, Nadja, Hoxha, Cora, Schäfer, Gertrud, Iden, Sandra, Bogeski, Ivan, Kummerow, Carsten, Schwarz, Eva C., and Hoth, Markus
- Subjects
CYTOTOXIC T cells ,KILLER cells ,HISTOCOMPATIBILITY class I antigens ,CANCER cells - Abstract
Cytotoxic T lymphocytes (CTL) and natural killer (NK) cells recognize and eliminate cancer cells. However, immune evasion, downregulation of immune function by the tumour microenvironment and resistance of cancer cells are major problems. Although CTL and NK cells are both important to eliminate cancer, most studies address them individually. We quantified sequential primary human CTL and NK cell cytotoxicity against the melanoma cell line SK‐Mel‐5. At high effector‐to‐target ratios, NK cells or melan‐A (MART‐1)‐specific CTL eliminated all SK‐Mel‐5 cells within 24 h, indicating that SK‐Mel‐5 cells are not resistant initially. However, at lower effector‐to‐target ratios, which resemble numbers of the immune contexture in human cancer, a substantial number of SK‐Mel‐5 cells survived. Pre‐exposure to CTL induced resistance in surviving SK‐Mel‐5 cells to subsequent CTL or NK cell cytotoxicity, and pre‐exposure to NK cells induced resistance in surviving SK‐Mel‐5 cells to NK cells. Higher human leucocyte antigen class I expression or interleukin‐6 levels were correlated with resistance to NK cells, whereas reduction in MART‐1 antigen expression was correlated with reduced CTL cytotoxicity. The CTL cytotoxicity was rescued beyond control levels by exogenous MART‐1 antigen. In contrast to the other three combinations, CTL cytotoxicity against SK‐Mel‐5 cells was enhanced following NK cell pre‐exposure. Our assay allows quantification of sequential CTL and NK cell cytotoxicity and might guide strategies for efficient CTL–NK cell anti‐melanoma therapies. Key points: Cytotoxic T lymphocytes (CTL) and natural killer (NK) cells eliminate cancer cells. Both CTL and NK cells attack the same targets, but most studies address them individually.In a sequential cytotoxicity model, the interdependence of antigen‐specific CTL and NK cell cytotoxicity against melanoma is quantified.High numbers of antigen‐specific CTL and NK cells eliminate all melanoma cells. However, lower numbers induce resistance if secondary CTL or NK cell exposure follows initial CTL exposure or if secondary NK cell exposure follows initial NK cell exposure. On the contrary, if secondary CTL exposure follows initial NK cell exposure, cytotoxicity is enhanced.Alterations in human leucocyte antigen class I expression and interleukin‐6 levels are correlated with resistance to NK cells, whereas a reduction in antigen expression is correlated with reduced CTL cytotoxicity; CTL cytotoxicity is rescued beyond control levels by exogenous antigen.This assay and the results on interdependencies will help us to understand and optimize immune therapies against cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
17. USP12 positively regulates M‐MDSC function to inhibit antitumour immunity through deubiquitinating and stabilizing p65.
- Author
-
Zhan, Xiaoxia, He, Qiuying, Sheng, Junli, Jiang, Xiaobing, Lin, Letao, Huang, Yulan, He, Shitong, Chen, Yitian, Li, Laisheng, Zeng, Zhijie, Hu, Shengfeng, Wang, Peng, and Zhang, Yanling
- Subjects
CYTOTOXIC T cells ,MYELOID-derived suppressor cells ,DEUBIQUITINATING enzymes ,NITRIC-oxide synthases ,IMMUNITY - Abstract
The relative abundance of myeloid‐derived suppressor cells (MDSCs) compared to cytotoxic T cells determines the outcomes of diseases and the efficacy of immunotherapy. Ubiquitin‐specific peptidase 12 (USP12), a member of the USP family of deubiquitinases, targets multiple signalling pathways and regulates diverse biological processes, including cell proliferation and survival. It is well known that ubiquitylation is an important mechanism for regulating the immune response. However, it is unclear whether USP12 regulates tumour growth by influencing MDSCs. In the present study, we reported that USP12 deficiency decreased infiltration and impaired the suppressor function of monocytic (M)‐MDSCs, resulting in increased CD8+ T‐cell response and decelerated tumour growth. USP12‐knockout M‐MDSCs were less potent in inhibiting the proliferation of CD8+ T cells and their ability to secrete IFN‐γ. Furthermore, USP12 deficiency inhibited the suppressor function of M‐MDSCs by downregulating the negative regulatory molecules inducible nitric oxide synthase and PD‐L1, through deubiquitinating and stabilizing p65. Our results suggest that USP12 is a positive regulator of M‐MDSCs and may serve as a potential target for antitumor therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
18. Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency.
- Author
-
Li, Zhilin, Lai, Xiaoqin, Fu, Shiqin, Ren, Long, Cai, Hao, Zhang, Hu, Gu, Zhongwei, Ma, Xuelei, and Luo, Kui
- Subjects
CYTOTOXIC T cells ,CELL death ,TUMOR microenvironment ,DRUG delivery systems ,PHOTOTHERMAL conversion ,IMMUNOTHERAPY - Abstract
Tumor immunotherapy is only effective in a fraction of patients due to a low response rate and severe side effects, and these challenges of immunotherapy in clinics can be addressed through induction of immunogenic cell death (ICD). ICD is elicited from many antitumor therapies to release danger associated molecular patterns (DAMPs) and tumor‐associated antigens to facilitate maturation of dendritic cells (DCs) and infiltration of cytotoxic T lymphocytes (CTLs). The process can reverse the tumor immunosuppressive microenvironment to improve the sensitivity of immunotherapy. Nanostructure‐based drug delivery systems (NDDSs) are explored to induce ICD by incorporating therapeutic molecules for chemotherapy, photosensitizers (PSs) for photodynamic therapy (PDT), photothermal conversion agents for photothermal therapy (PTT), and radiosensitizers for radiotherapy (RT). These NDDSs can release loaded agents at a right dose in the right place at the right time, resulting in greater effectiveness and lower toxicity. Immunotherapeutic agents can also be combined with these NDDSs to achieve the synergic antitumor effect in a multi‐modality therapeutic approach. In this review, NDDSs are harnessed to load multiple agents to induce ICD by chemotherapy, PDT, PTT, and RT in combination of immunotherapy to promote the therapeutic effect and reduce side effects associated with cancer treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
19. Application of a patient‐centered reverse translational systems‐based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitors.
- Author
-
Kim, Sarah, Lahu, Gezim, Vakilynejad, Majid, Soldatos, Theodoros G., Jackson, David B., Lesko, Lawrence J., and Trame, Mirjam N.
- Subjects
DRUG side effects ,IPILIMUMAB ,IMMUNE checkpoint inhibitors ,PEMBROLIZUMAB ,CYTOTOXIC T cells ,BIOLOGICAL systems ,BIOLOGICAL databases ,CHEMICAL systems - Abstract
Immunotherapy became a key pillar of cancer therapeutics with the approvals of ipilimumab, nivolumab, and pembrolizumab, which inhibit either cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) or programmed death‐1 (PD‐1) that are negative regulators of T‐cell activation. However, boosting T‐cell activation is often accompanied by autoimmunity, leading to adverse drug reactions (ADRs), including high grade 3–4 colitis and its severe complications whose prevalence may reach 14% for combination checkpoint inhibitors. In this research, we investigated how mechanistic differences between anti‐CTLA‐4 (ipilimumab) and anti‐PD‐1 (nivolumab and pembrolizumab) affect colitis, a general class toxicity. The data analytical platform Molecular Health Effect was utilized to map population ADR data from the US Food and Drug Administration (FDA) Adverse Event Reporting System to chemical and biological databases for hypothesis generation regarding the underlying molecular mechanisms causing colitis. Disproportionality analysis was used to assess the statistical relevance between adverse events of interest and molecular causation. We verified that the anti‐CTLA‐4 drug is associated with an approximately three‐fold higher proportional reporting ratio associated with colitis than those of the anti‐PD‐1 drugs. The signal of the molecular mechanisms, including signaling pathways of inflammatory cytokines, was statistically insignificant to test the hypothesis that the severer rate of colitis associated with ipilimumab would be due to a greater magnitude of T‐cell activation as a result of earlier response of the anti‐CTLA‐4 drug in the immune response. This patient‐centered systems‐based approach provides an exploratory process to better understand drug pair adverse events at pathway and target levels through reverse translation from postmarket surveillance safety reports. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
20. Tumor Derived Extracellular Vesicles Drive T Cell Exhaustion in Tumor Microenvironment through Sphingosine Mediated Signaling and Impacting Immunotherapy Outcomes in Ovarian Cancer.
- Author
-
Gupta, Prachi, Kadamberi, Ishaque Pulikkal, Mittal, Sonam, Tsaih, Shirng-Wern, George, Jasmine, Kumar, Sudhir, Vijayan, Dileep K., Geethadevi, Anjali, Parashar, Deepak, Topchyan, Paytsar, McAlarnen, Lindsey, Volkman, Brian F., Weiguo Cui, Zhang, Kam Y. J., Di Vizio, Dolores, Chaluvally-Raghavan, Pradeep, and Pradeep, Sunila
- Subjects
EXTRACELLULAR vesicles ,OVARIAN cancer ,T cells ,TUMOR microenvironment ,SPHINGOSINE ,CYTOTOXIC T cells ,T-cell exhaustion - Abstract
SPHK1 (sphingosine kinase-1) catalyzes the phosphorylation of sphingosine to sphingosine-1-phosphate (S1P), is found to be highly expressed in solid tumors. Here, extracellular vesicles (EVs) are identified as the key transporters of SPHK1 to the tumor microenvironment. Consequently, SPHK1-packaged EVs elevate S1P levels in the tumor microenvironment, where S1P appears as an immunosuppressive agent. However, the exact mechanism of how S1P mediates its immunosuppressive effects in cancer is not understood. It is investigated that S1P can induce T cell exhaustion. S1P can also upregulate programmed death ligand-1 (PDL-1) expression through E2F1-mediated transcription. Notably, an SPHK1 inhibitor PF543 improves T cell-mediated cytotoxicity. Furthermore, combining PF543 with an anti-PD-1 antibody reduces tumor burden and metastasis more effectively than PF543 alone in vivo. These data demonstrate a previously unrecognized mechanism of how SPHK1-packaged EVs contribute to the progression of ovarian cancer and thus present the potential clinical application of inhibiting SPHK1/S1P signaling to improve immune checkpoint blockage (anti-PD-1 antibody) therapy in ovarian cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
21. Phenotype‐Based Isolation of Antigen‐Specific CD4+ T Cells in Autoimmunity: A Study of Celiac Disease.
- Author
-
Christophersen, Asbjørn, Dahal‐Koirala, Shiva, Chlubnová, Markéta, Jahnsen, Jørgen, Lundin, Knut E. A., and Sollid, Ludvig M.
- Subjects
CELIAC disease ,T cells ,AUTOIMMUNITY ,PEPTIDES ,CYTOTOXIC T cells ,CD4 antigen ,EPITOPES - Abstract
The pathogenic immune response in celiac disease (CeD) is orchestrated by phenotypically distinct CD4+ T cells that recognize gluten epitopes in the context of disease‐associated HLA‐DQ allotypes. Cells with the same distinct phenotype, but with elusive specificities, are increased across multiple autoimmune conditions. Here, whether sorting of T cells based on their distinct phenotype (Tphe cells) yields gluten‐reactive cells in CeD is tested. The method′s efficiency is benchmarked by parallel isolation of gluten‐reactive T cells (Ttet cells), using HLA‐DQ:gluten peptide tetramers. From gut biopsies of 12 untreated HLA‐DQ2.5+ CeD patients, Ttet+/Tphe+, Ttet−/Tphe+, and Ttet−/Tphe− cells are sorted for single‐cell T‐cell receptor (TCR)‐sequencing (n = 8) and T‐cell clone (TCC)‐generation (n = 5). The generated TCCs are TCR sequenced and tested for their reactivity against deamidated gluten. Gluten‐reactivity is observed in 91.2% of Ttet+/Tphe+ TCCs, 65.3% of Ttet−/Tphe+ TCCs and 0% of Ttet−/Tphe− TCCs. TCR sequencing reveals clonal expansion and sequence sharing across patients, features reflecting antigen‐driven responses. The feasibility to isolate antigen‐specific CD4+ T cells by the sole use of phenotypic markers in CeD outlines a potential avenue for characterizing disease‐driving CD4+ T cells in autoimmune conditions. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
22. Association of human leukocyte antigen‐B*13:01 with dapsone‐induced liver injury.
- Author
-
Devarbhavi, Harshad, Patil, Mallikarjun, and Menon, Mahesh
- Subjects
LIVER injuries ,HLA histocompatibility antigens ,DRUG side effects ,LEUCOCYTES ,CYTOTOXIC T cells - Abstract
Human leukocyte antigens (HLA) have been linked to adverse drug reactions. Generally, HLA association is phenotype specific and is related to either liver or skin injury. HLA‐A*13:01 has been linked to dapsone‐induced severe cutaneous drug reactions and its role in drug‐induced liver injury (DILI) is unclear. In our series, all of the four patients with immunoallergic dapsone DILI were carrying HLA‐B*13:01 compared to its prevalence of 1–12% among Indians. HLA‐B*13:01 plays a role not only in dapsone‐induced severe cutaneous adverse reaction (SCAR) but also in dapsone‐induced liver injury with immunoallergic features and highlights the role of adaptive immune response in the pathogenesis of both liver and skin injury and associated other organ involvement. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
23. Targeted Anti‐Tumor Immunotherapy Using Tumor Infiltrating Cells.
- Author
-
Xie, Yifan, Xie, Feng, Zhang, Lei, Zhou, Xiaoxue, Huang, Jun, Wang, Fangwei, Jin, Jin, Zhang, Long, Zeng, Linghui, and Zhou, Fangfang
- Subjects
T cells ,TUMOR-infiltrating immune cells ,IMMUNE checkpoint proteins ,CYTOTOXIC T cells ,B cells ,CD8 antigen ,CD4 antigen - Abstract
In the tumor microenvironment, T cells, B cells, and many other cells play important and distinct roles in anti‐tumor immunotherapy. Although the immune checkpoint blockade and adoptive cell transfer can elicit durable clinical responses, only a few patients benefit from these therapies. Increased understanding of tumor‐infiltrating immune cells can provide novel therapies and drugs that induce a highly specific anti‐tumor immune response to certain groups of patients. Herein, the recent research progress on tumor‐infiltrating B cells and T cells, including CD8+ T cells, CD4+ T cells, and exhausted T cells and their role in anti‐tumor immunity, is summarized. Moreover, several anti‐tumor therapy approaches are discussed based on different immune cells and their prospects for future applications in cancer treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
24. Tumor‐associated macrophages in immunotherapy.
- Author
-
Yan, Shijia and Wan, Guohui
- Subjects
IMMUNOTHERAPY ,CANCER invasiveness ,MACROPHAGES ,CANCER relapse ,IMMUNE system ,CYTOTOXIC T cells - Abstract
Tumor‐associated macrophages (TAMs) are essential components of the tumor microenvironment involved in the progression and metastasis of cancer. They are intimately involved in angiogenesis and immunosuppression in normal and malignant tissues, as well as pro‐fibrotic activities. With the development of immunotherapy, eradication of cancer cells through activation of the innate immune system has achieved inspiring results, whereas only a handful of patients show a durable response. The tumor‐suppressive environment has been investigated with respect to playing a vital role in cancer relapse. In this review, we uncover the heterogeneity of the origin of TAMs, as well as the functions of TAMs in tumor progression associated with intricate regulatory networks in the tumor microenvironment, aiming to inspire therapeutic insight for tumor immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
25. HOIL‐1‐catalysed, ester‐linked ubiquitylation restricts IL‐18 signaling in cytotoxic T cells but promotes TLR signalling in macrophages.
- Author
-
Petrova, Tsvetana, Zhang, Jiazhen, Nanda, Sambit K., Figueras‐Vadillo, Clara, and Cohen, Philip
- Subjects
CYTOTOXIC T cells ,UBIQUITINATION ,GRANULOCYTE-macrophage colony-stimulating factor ,CELL receptors ,MACROPHAGES ,CYTOKINES - Abstract
The atypical E3 ligase HOIL‐1 forms ester bonds between ubiquitin and serine/threonine residues in proteins, but the physiological roles of this unusual modification are unknown. We now report that IL‐18 signalling leading to the production of interferon γ (IFNγ) and granulocyte–macrophage colony‐stimulating factor (GM‐CSF) is enhanced in cytotoxic T cells from knock‐in mice expressing the E3 ligase‐inactive HOIL‐1[C458S] mutant, demonstrating that the formation of HOIL‐1‐catalysed ester‐linked ubiquitin bonds restricts the activation of this pathway. We show that the interaction of IRAK2 with TRAF6 is required for IL‐18‐stimulated IFN‐γ and GM‐CSF production, and that the increased production of these cytokines in cytotoxic T cells from HOIL‐1[C458S] mice correlates with an increase in both the number and size of the Lys63/Met1‐linked hybrid ubiquitin chains attached to IRAK2 in these cells. In contrast, the secretion of IL‐12 and IL‐6 and the formation of il‐12 and il‐6 mRNA induced in bone marrow‐derived macrophages (BMDMs) by prolonged stimulation with TLR‐activating ligands that signal via myddosomes, which also requires the interaction of IRAK2 with TRAF6, were not increased but modestly reduced in HOIL‐1[C458S] BMDM. The decreased production of these cytokines correlated with reduced ubiquitylation of IRAK2. Our results establish that changes in HOIL‐1‐catalysed ester‐linked ubiquitylation can promote or reduce cytokine production depending on the ligand, receptor and immune cell and may be explained by differences in the ubiquitylation of IRAK2. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
26. Standing on the shoulders of microbes: How cancer biologists are expanding their view of hard‐to‐kill persister cells.
- Subjects
BIOLOGISTS ,CYTOTOXIC T cells - Abstract
As both antibiotics and chemotherapy treatments target proliferating cells, it is not surprising that cell dormancy was linked to cell persistence in both cases. While classical persisters are common to both bacteria and cancer cells, other persister classes are cancer-specific and are associated with the ability of cancer cells to probe a wide range of cells states and lineage trajectories. gl So why can some bacteria persist in the face of therapy? Similar to persister bacterial cells that survive antibiotic treatments, some cancer cells can evade drug treatments. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
27. Extreme prematurity and sepsis strongly influence frequencies and functional characteristics of circulating γδ T and natural killer cells.
- Author
-
Rahman Qazi, Khaleda, Jensen, Georg B, Heiden, Marieke, Björkander, Sophia, Marchini, Giovanna, Jenmalm, Maria C, Abrahamsson, Thomas, and Sverremark‐Ekström, Eva
- Subjects
KILLER cells ,MONONUCLEAR leukocytes ,CYTOTOXIC T cells ,NEONATAL sepsis ,SEPSIS ,CELL populations - Abstract
Objectives: Extremely low gestational age neonates with extremely low birthweight (ELGAN/ELBW) are highly susceptible to infection. This is linked to their relatively immature immune system which is not yet fully compatible with an extra‐uterine environment. Here, we performed a longitudinal characterisation of unconventional T and natural killer (NK) cells in ELGAN/ELBW during their first months of life. Methods: Peripheral blood mononuclear cells were collected from 97 ELGAN/ELBW at 14 and 28 days of life and at a time point corresponding to postmenstrual week 36 + 0. γδ T‐cell, NKT‐cell, mucosa‐associated invariant T‐cell and NK cell frequencies and characteristics were analysed by flow cytometry. As control, cells from 14‐day‐old full‐term (FT) infants were included. Results: Extreme prematurity had significant bearing on γδ T‐cell and NK cell frequencies and characteristics. ELGAN/ELBW had significantly higher proportions of γδ T cells that were skewed towards effector and effector memory phenotypes, characteristics that were maintained throughout the study period. Expression of the gut homing receptor CCR9 was also more common in γδ T cells from ELGAN/ELBW. Conversely, NK cell frequencies were markedly lower and skewed towards a cytotoxic phenotype in the ELGAN/ELBW group at 14 days of age. Culture‐proven sepsis with an onset during the first 14 days after birth further manifested these differences in the γδ T‐ and NK cell populations at 14 days of age. Conclusion: Prematurity strongly influences the levels of γδ T and NK cells, in particular in cases where sepsis debuts during the first 2 weeks of life. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
28. Professional killers: The role of extracellular vesicles in the reciprocal interactions between natural killer, CD8+ cytotoxic T‐cells and tumour cells.
- Author
-
Del Vecchio, Filippo, Martinez‐Rodriguez, Verena, Schukking, Monique, Cocks, Alexander, Broseghini, Elisabetta, and Fabbri, Muller
- Subjects
CYTOTOXIC T cells ,KILLER cells ,T cells ,CANCER cells ,TUMOR microenvironment ,DEFENSE reaction (Physiology) ,ROADKILL - Abstract
Extracellular vesicles (EVs) mediate the cross‐talk between cancer cells and the cells of the surrounding Tumour Microenvironment (TME). Professional killer cells include Natural Killer (NK) cells and CD8+ Cytotoxic T‐lymphocytes (CTLs), which represent some of the most effective immune defense mechanisms against cancer cells. Recent evidence supports the role of EVs released by NK cells and CTLs in killing cancer cells, paving the road to a possible therapeutic role for such EVs. This review article provides the state‐of‐the‐art knowledge on the role of NK‐ and CTL‐derived EVs as anticancer agents, focusing on the different functions of different sub‐types of EVs. We also reviewed the current knowledge on the effects of cancer‐derived EVs on NK cells and CTLs, identifying areas for future investigation in the emerging new field of EV‐mediated immunotherapy of cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
29. Inhibition of galectin‐3 augments the antitumor efficacy of PD‐L1 blockade in non‐small‐cell lung cancer.
- Author
-
Zhang, Hongxin, Liu, Pengfei, Zhang, Yan, Han, Lujun, Hu, Zhihui, Cai, Ziqi, and Cai, Jianhui
- Subjects
NON-small-cell lung carcinoma ,PROGRAMMED cell death 1 receptors ,PROGRAMMED death-ligand 1 ,GALECTINS ,CYTOTOXIC T cells ,LUNG cancer ,MONOCLONAL antibodies - Abstract
Multiple clinical trials have shown that monoclonal antibodies (mAbs) against programmed death‐ligand 1 (PD‐1/PD‐L1) can benefit patients with lung cancer by increasing their progression‐free survival and overall survival. However, a significant proportion of patients do not respond to anti‐PD‐1/PD‐L1 mAbs. In the present study, we investigated whether galectin (Gal)‐3 inhibitors can enhance the antitumor effect of PD‐L1 blockade. Using the NSCLC‐derived cell line A549, we examined the expression of Gal‐3 in lung cancer cells under hypoxic conditions and investigated the regulatory effect of Gal‐3 on PD‐L1 expression, which is mediated by the STAT3 pathway. We also explored whether Gal‐3 inhibition can facilitate the cytotoxic effect of T cells induced by PD‐L1 blockade. The effects of combined use of a Gal‐3 inhibitor and PD‐L1 blockade on tumor growth and T‐cell function were also investigated, and we found that hypoxia increased the expression and secretion of Gal‐3 by lung cancer cells. Gal‐3 increased PD‐L1 expression via the upregulation of STAT3 phosphorylation, and administration of a Gal‐3 inhibitor enhanced the effect of PD‐L1 blockade on the cytotoxic activity of T cells against cancer cells in vitro. In a mouse xenograft model, the combination of a Gal‐3 inhibitor and PD‐L1 blockade synergistically suppressed tumor growth. Furthermore, the administration of a Gal‐3 inhibitor enhanced T‐cell infiltration and granzyme B release in tumors. Collectively, our results show that Gal‐3 increases PD‐L1 expression in lung cancer cells and that the administration of a Gal‐3 inhibitor as an adjuvant enhanced the antitumor activity of PD‐L1 blockade. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
30. Inflammation, ictogenesis, and epileptogenesis: An exploration through human disease.
- Author
-
Tan, Tracie Huey‐Lin, Perucca, Piero, O'Brien, Terence J., Kwan, Patrick, and Monif, Mastura
- Subjects
ANTI-NMDA receptor encephalitis ,CYTOTOXIC T cells ,DIAGNOSIS ,NEUROLOGICAL disorders ,ENCEPHALITIS ,COMPLEMENT activation - Abstract
Epilepsy is seen historically as a disease of aberrant neuronal signaling manifesting as seizures. With the discovery of numerous auto‐antibodies and the subsequent growth in understanding of autoimmune encephalitis, there has been an increasing emphasis on the contribution of the innate and adaptive immune system to ictogenesis and epileptogenesis. Pathogenic antibodies, complement activation, CD8+ cytotoxic T cells, and microglial activation are seen, to various degrees, in different seizure‐associated neuroinflammatory and autoimmune conditions. These aberrant immune responses are thought to cause disruptions in neuronal signaling, generation of acute symptomatic seizures, and, in some cases, the development of long‐term autoimmune epilepsy. Although early treatment with immunomodulatory therapies improves outcomes in autoimmune encephalitides and autoimmune epilepsies, patient identification and treatment selection are not always clear‐cut. This review examines the role of the different components of the immune system in various forms of seizure disorders including autoimmune encephalitis, autoimmune epilepsy, Rasmussen encephalitis, febrile infection–related epilepsy syndrome (FIRES), and new‐onset refractory status epilepticus (NORSE). In particular, the pathophysiology and unique cytokine profiles seen in these disorders and their links with diagnosis, prognosis, and treatment decision‐making are discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
31. Actin reorganization at the centrosomal area and the immune synapse regulates polarized secretory traffic of multivesicular bodies in T lymphocytes.
- Author
-
Bello-Gamboa, Ana, Velasco, Marta, Moreno, Solange, Herranz, Gonzalo, Ilie, Roxana, Huetos, Silvia, Dávila, Sergio, Sánchez, Alicia, Bernardino De La Serna, Jorge, Calvo, Víctor, and Izquierdo, Manuel
- Subjects
GREEN fluorescent protein ,T cells ,PROTEIN kinase C ,CYTOTOXIC T cells ,ANTIGEN presenting cells ,ACTIN ,CYTOSKELETON - Abstract
T-cell receptor stimulation induces the convergence of multivesicular bodies towards the microtubule-organizing centre (MTOC) and the polarization of the MTOC to the immune synapse (IS). These events lead to exosome secretion at the IS. We describe here that upon IS formation centrosomal area F-actin decreased concomitantly with MTOC polarization to the IS. PKCδ-interfered T cell clones showed a sustained level of centrosomal area F-actin associated with defective MTOC polarization. We analysed the contribution of two actin cytoskeleton-regulatory proteins, FMNL1 and paxillin, to the regulation of cortical and centrosomal F-actin networks. FMNL1 β phosphorylation and F-actin reorganization at the IS were inhibited in PKCδ-interfered clones. F-actin depletion at the central region of the IS, a requirement for MTOC polarization, was associated with FMNL1 β phosphorylation at its C-terminal, autoregulatory region. Interfering all FMNL1 isoforms prevented MTOC polarization; nonetheless, FMNL1 β re-expression restored MTOC polarization in a centrosomal area F-actin reorganization-independent manner. Moreover, PKCδ-interfered clones exhibited decreased paxillin phosphorylation at the MTOC, which suggests an alternative actin cytoskeleton regulatory pathway. Our results infer that PKCδ regulates MTOC polarization and secretory traffic leading to exosome secretion in a coordinated manner by means of two distinct pathways, one involving FMNL1 β regulation and controlling F-actin reorganization at the IS, and the other, comprising paxillin phosphorylation potentially controlling centrosomal area F-actin reorganization. Ab, antibody; AICD, activation-induced cell death; AIP, average intensity projection; APC, antigen-presenting cell; BCR, B-cell receptor for antigen;
C , centre of mass; cent2, centrin 2; cIS, central region of the immune synapse; CMAC, CellTracker™ Blue (7-amino-4-chloromethylcoumarin); cSMAC, central supramolecular activation cluster; CTL, cytotoxic T lymphocytes; DAG, diacylglycerol; DGKα, diacylglycerol kinase α; Dia1, Diaphanous-1; dSMAC, distal supramolecular activation cluster; ECL, enhanced chemiluminescence; ESCRT, endosomal sorting complex required for traffic; F-actin, filamentous actin; Fact-low cIS, F-actin-low region at the centre of the immune synapse; FasL, Fas ligand; FMNL1, formin-like 1; fps, frames per second; GFP, green fluorescent protein; HBSS, Hank's balanced salt solution; HRP, horseradish peroxidase; ILV, intraluminal vesicles; IS, immune synapse; MFI, mean fluorescence intensity; MHC, major histocompatibility complex; MIP, maximal intensity projection; MVB, multivesicular bodies; MTOC, microtubule-organizing centre; NS, not significant; PBL, peripheral blood lymphocytes; PKC, protein kinase C; PKCδ, protein kinase C δ isoform; PLC, phospholipase C; PMA, phorbol myristate acetate; Pol. Index, polarization index; pSMAC, peripheral supramolecular activation cluster; PSF, point spread function; ROI, region of interest; SD, standard deviation; shRNA, short hairpin RNA; SEE, Staphylococcus enterotoxin E; SMAC, supramolecular activation cluster; TCR, T-cell receptor for antigen; T-helper (Th); TRANS, transmittance; WB, Western blot. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
32. Identification of the prognostic and immunotherapeutic potential of L antigen family member 3 in malignant pleural mesothelioma.
- Author
-
Dong, Xubin, Song, Jingjing, He, Minzhi, Sun, Jiawen, Tao, Endong, Zhang, Xiaohua, and Li, Quan
- Subjects
TOXICOLOGY of asbestos ,PLEURA ,IMMUNE checkpoint inhibitors ,CYTOTOXIC T cells ,ANTIGENS ,KILLER cells - Abstract
Dear Editor, Malignant pleural mesothelioma (MPM) is the most common malignant mesothelioma and difficult to treat. F, The anti-CTLA-4 combined anti-PD-L1 therapies response in the high-LAGE3 group and low-LAGE3 group. Compared with and the high-LAGE3 group, the low-LAGE3 group showed ninefold anti-CTLA-4 response rate (Figure 2C, I P i = .0011) and 11-fold anti-CTLA-4 combined anti-PD-L1 response rate (Figure 2F, I P i = .0001). [Extracted from the article]
- Published
- 2020
- Full Text
- View/download PDF
33. Immunosuppressive role of CD11b+CD33+HLA‐DR− myeloid‐derived suppressor cells‐like blast subpopulation in acute myeloid leukemia.
- Author
-
Hyun, Shin Young, Na, Eun Jung, Jang, Ji Eun, Chung, Haerim, Kim, Soo Jeong, Kim, Jin Seok, Kong, Jee Hyun, Shim, Kwang Yong, Lee, Jong In, Min, Yoo Hong, and Cheong, June‐Won
- Subjects
ACUTE myeloid leukemia ,CYTOTOXIC T cells ,HEMATOPOIETIC stem cell transplantation ,NITRIC-oxide synthases ,BONE marrow cells - Abstract
Objective: Myeloid‐derived suppressor cells (MDSCs) facilitate tumor growth and development by suppressing T cell function; however, their role in acute myeloid leukemia (AML) remains unclear. Here, we investigated the immunosuppressive role and prognostic value of blasts with an MDSC‐like phenotype. Methods: CD11b+CD33+HLA‐DR− MDSC‐like blasts from bone marrow mononuclear cells of patients with AML were analyzed. To investigate their T cell‐suppressing function, MDSC‐like blasts were isolated using flow cytometry and co‐cultured with CD8+ cytotoxic T cells and NB4 leukemic cells. Treatment outcomes were then compared between the MDSC‐like blasts low (≤9.76%) and high (>9.76%) groups to identify clinical significance. Results: MDSC‐like blasts showed higher expression of arginase‐1 and inducible nitric oxide synthase. Isolated MDSC‐like blasts significantly suppressed CD8+ T cell proliferation induced by phytohemagglutinin A. NB4 cell proliferation was significantly suppressed upon co‐culture with CD8+ cytotoxic T cells and partially restored upon co‐culture with MDSC‐like blasts. Patients with high MDSC‐like blasts at diagnosis showed substantially shorter overall survival and leukemia‐free survival relative to low MDSC‐like blasts patients, with subgroup analysis showing statistically significant differences in patients not receiving allogeneic hematopoietic stem cell transplantation. Conclusion: We demonstrated that MDSC‐like blasts drive AML‐specific immune‐escape mechanisms by suppressing T cell proliferation and restoring T cell‐suppressed NB4 cell proliferation, with clinically higher fractions of MDSC‐like blasts at diagnosis resulting in poor prognosis. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
34. Chimeric antigen receptor T‐cell therapies: Optimising the dose.
- Author
-
Dasyam, Nathaniel, George, Philip, and Weinkove, Robert
- Subjects
CD19 antigen ,CHIMERIC antigen receptors ,CYTOTOXIC T cells ,PHARMACOKINETICS - Abstract
Lymphocytes such as T‐cells can be genetically transduced to express a synthetic chimeric antigen receptor (CAR) that re‐directs their cytotoxic activity against a tumour‐expressed antigen of choice. Autologous (patient‐derived) CAR T‐cells have been licensed to treat certain relapsed and refractory B‐cell malignancies, and numerous CAR T‐cell products are in clinical development. As living gene‐modified cells, CAR T‐cells exhibit unique pharmacokinetics, typically proliferating within the recipient during the first 14 days after administration before contracting in number, and sometimes exhibiting long‐term persistence. The relationship between CAR T‐cell dose and exposure is highly variable, and may be influenced by CAR design, patient immune function at the time of T‐cell harvest, phenotype of the CAR T‐cell product, disease burden, lymphodepleting chemotherapy and subsequent immunomodulatory therapies. Recommended CAR T‐cell doses are typically established for a specific product and indication, although for some products, stratification of dose based on disease burden may mitigate toxicity while maintaining efficacy. Re‐evaluation of CAR T‐cell dosing may be necessary following changes to the lymphodepleting regimen, for different disease indications, and following significant manufacturing changes, if product comparability cannot be demonstrated. Dose escalation trials have typically employed 3 + 3 designs, although this approach has limitations, and alternative phase I trial designs may facilitate the identification of CAR T‐cell doses that strike an optimal balance of safety, efficacy and manufacturing feasibility. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
35. Modulation of gut microbiota mediates berberine‐induced expansion of immuno‐suppressive cells to against alcoholic liver disease.
- Author
-
Li, Sha, Wang, Ning, Tan, Hor‐Yue, Chueng, Fan, Zhang, Zhang‐Jin, Yuen, Man‐Fung, and Feng, Yibin
- Subjects
ALCOHOLIC liver diseases ,GUT microbiome ,ISOQUINOLINE alkaloids ,CYTOTOXIC T cells ,BERBERINE ,SUPPRESSOR cells - Abstract
Background: Berberine is an isoquinoline alkaloid compound derived from many herbs, which has been used extensively to improve liver function. But action mechanism of its hepatoprotection in alcoholic liver disease (ALD) is far from being clear. Aim: To investigate the underlying mechanism of berberine's therapeutic effect on ALD associated with gut microbiota‐immune system axis. Method: An animal model fed with ethanol that mimics drinking pattern ideally in ALD patients was established. Liver function was evaluated by biochemical test and histological examination. Immune cells were detected by flow cytometry and feces samples were collected for 16S rRNA gene amplicon sequencing. Results: We first reported the promising beneficial effect of berberine on ameliorating acute‐on‐chronic alcoholic hepatic damage and explored the underlying mechanism involving gut microbiota‐immune system axis. Notably, berberine activated a population with immune suppressive function, defined as granulocytic‐ myeloid‐derived suppressor cell (G‐MDSC)‐like population, in the liver of mice with alleviating alcohol‐induced hepatic injury. Berberine remarkably enhanced the increase of G‐MDSC‐like cells in blood and liver and decreased cytotoxic T cells correspondingly. Suppression of G‐MDSC‐like population significantly attenuated the protective effect of berberine against alcohol. Berberine activated IL6/STAT3 signaling in in vitro culture of G‐MSDCs‐like population, while inhibition of STAT3 activity attenuated the activation of this population by berberine. Moreover, berberine changed the overall gut microbial community, primarily increased the abundance of Akkermansia muciniphila. Of note, depletion of gut microbiota abolished the inducing effect of berberine on G‐MDSC‐like population, and attenuated its hepatoprotective effect against alcohol in mice, suggesting intestinal flora might be involved in mediating the expansion of this protective population. Conclusion: Collectively, this study delivered insight into the role of immunosuppressive response in ALD, and facilitated the understanding of the pharmacological effects and action mechanisms of berberine. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
36. Prognostic significance of immune landscape in tumour microenvironment of endometrial cancer.
- Author
-
Li, Bi‐Lan and Wan, Xiao‐Ping
- Subjects
ENDOMETRIAL cancer ,CYTOTOXIC T cells ,KILLER cells ,DENDRITIC cells ,CLUSTER analysis (Statistics) ,TUMORS - Abstract
Tumour microenvironment (TME) is crucial to tumorigenesis. This study aimed to uncover the differences in immune phenotypes of TME in endometrial cancer (EC) using Uterine Corpus Endometrial Carcinoma (UCEC) cohort and explore the prognostic significance. We employed GVSA enrichment analysis to cluster The Cancer Genome Atlas (TCGA) EC samples into immune signature cluster modelling, evaluated immune cell profiling in UCEC cohort (n = 538) and defined four immune subtypes of EC. Next, we analysed the correlation between immune subtypes and clinical data including patient prognosis. Furthermore, we analysed the expression of immunomodulators and DNA methylation modification. The profiles of immune infiltration in TCGA UCEC cohort showed significant difference among four immune subtypes of EC. Among each immune subtype, natural killer T cells (NKT), dendritic cells (DCs) and CD8+T cells were significantly associated with EC patients survival. Each immune subtype exhibited specific molecular classification, immune cell characterization and immunomodulators expression. Moreover, the expression immunomodulators were significantly related to DNA methylation level. In conclusion, the identification of immune subtypes in EC tissues could reveal unique immune microenvironments in EC and predict the prognosis of EC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
37. CD279 mediates the homeostasis and survival of regulatory T cells by enhancing T cell and macrophage interactions.
- Author
-
Liu, Yang, Gao, Yuting, Hao, Huiqin, and Hou, Tiezheng
- Subjects
SUPPRESSOR cells ,T cells ,ANTIGEN presenting cells ,BONE marrow cells ,INTERLEUKIN-7 ,CYTOTOXIC T cells ,CELL membranes ,IMMUNE complexes - Abstract
CD279 is a cell surface protein predominantly expressed on T cells. Its ligands CD273 and CD274 are expressed on antigen‐presenting cells and tumors. CD279 has been shown to act as an important immune check point by inhibiting CD8 T cell activation, and antibodies against CD279 enhance T cell‐mediated cytotoxic function. However, whether CD279 has other functions in CD4 T cell homeostasis or in mediating T cell interactions with antigen‐presenting cells remains unclear. In the present study, we show that antibody‐mediated inhibition of CD279 reduces T cell survival in bone marrow in vivo. Unexpectedly, CD279 blockade also compromised regulatory T cell and macrophage interactions by reducing their contact time. The observation that the CD273 antagonist had little effect suggests that CD274 (the second ligand of CD279) plays a more central role in contact between conventional T cells (Tcon) and macrophages. The results of the present study suggest that both CD279 ligands contribute to the interaction length between T cells and macrophages as a mechanism of maintaining Treg homeostasis. Furthermore, CD273 and CD274 are not redundant ligands because CD274 may have unique effects on Tcon in this complex immune axis. Therefore, ligand selection for check point blockade as a tool for cancer immunotherapy has important implications with respect to anti‐tumor T cell activation and the avoidance of side effects. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
38. Verteporfin inhibits oxidative phosphorylation and induces cell death specifically in glioma stem cells.
- Author
-
Kuramoto, Kenta, Yamamoto, Masahiro, Suzuki, Shuhei, Sanomachi, Tomomi, Togashi, Keita, Seino, Shizuka, Kitanaka, Chifumi, and Okada, Masashi
- Subjects
STEM cells ,OXIDATIVE phosphorylation ,CELL death ,CANCER stem cells ,GLIOBLASTOMA multiforme ,ANTIBODY-dependent cell cytotoxicity ,CYTOTOXIC T cells - Abstract
Glioblastoma multiforme (GBM) is the most malignant primary brain tumour in adults. Since glioma stem cells (GSCs) are associated with therapeutic resistance as well as the initiation and recurrence in GBM, therapies targeting GSCs are considered to be effective for long‐term survival in GBM. Several reports suggested that oxidative phosphorylation (OXPHOS) of cancer stem cells is important for their survival; however, the requirement of OXPHOS in GSCs remains unclear. Few effective and safe agents that target GSC mitochondria are available in clinical settings. In this study, we demonstrated that GSCs had high OXPHOS activity compared with isogenic differentiated GSCs and that GSC survival depended on their OXPHOS activity. Remarkably, we showed that complexes III and IV had broad therapeutic windows and that the expression levels of mitochondrial DNA‐coded components of complexes III and IV were elevated in GSCs compared with differentiated GSCs. Moreover, our search of the Food and Drug Administration‐approved drugs for those targeting GSC mitochondria revealed that verteporfin (Visudyne®), a drug approved for macular degeneration, was a novel GSC‐specific cytotoxic compound that reduced OXPHOS activity. Importantly, the cytotoxic effect of verteporfin was specific to GSCs without any toxicity to normal cells, and the IC50 of approximately 200 nm was ten times less than its maximum blood concentration in humans. Overall, these findings indicated that high mitochondrial OXPHOS of GSCs is a potential GSC‐specific vulnerability and that clinically available drugs, such as verteporfin, might become novel GSC‐specific cytotoxic agents. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
39. ImmuCellAI: A Unique Method for Comprehensive T‐Cell Subsets Abundance Prediction and its Application in Cancer Immunotherapy.
- Author
-
Miao, Ya‐Ru, Zhang, Qiong, Lei, Qian, Luo, Mei, Xie, Gui‐Yan, Wang, Hongxiang, and Guo, An‐Yuan
- Subjects
CYTOTOXIC T cells ,FORECASTING ,IMMUNOTHERAPY ,T cells ,DENDRITIC cells ,CANCER treatment - Abstract
The distribution and abundance of immune cells, particularly T‐cell subsets, play pivotal roles in cancer immunology and therapy. T cells have many subsets with specific function and current methods are limited in estimating them, thus, a method for predicting comprehensive T‐cell subsets is urgently needed in cancer immunology research. Here, Immune Cell Abundance Identifier (ImmuCellAI), a gene set signature‐based method, is introduced for precisely estimating the abundance of 24 immune cell types including 18 T‐cell subsets, from gene expression data. Performance evaluation on both the sequencing data with flow cytometry results and public expression data indicate that ImmuCellAI can estimate the abundance of immune cells with superior accuracy to other methods especially on many T‐cell subsets. Application of ImmuCellAI to immunotherapy datasets reveals that the abundance of dendritic cells, cytotoxic T, and gamma delta T cells is significantly higher both in comparisons of on‐treatment versus pre‐treatment and responders versus non‐responders. Meanwhile, an ImmuCellAI result‐based model is built for predicting the immunotherapy response with high accuracy (area under curve 0.80–0.91). These results demonstrate the powerful and unique function of ImmuCellAI in tumor immune infiltration estimation and immunotherapy response prediction. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
40. The disruption of invariant natural killer T cells exacerbates cardiac hypertrophy and failure caused by pressure overload in mice.
- Author
-
Takahashi, Masashige, Kinugawa, Shintaro, Takada, Shingo, Kakutani, Naoya, Furihata, Takaaki, Sobirin, Mochamad Ali, Fukushima, Arata, Obata, Yoshikuni, Saito, Akimichi, Ishimori, Naoki, Iwabuchi, Kazuya, and Tsutsui, Hiroyuki
- Subjects
CYTOTOXIC T cells ,KILLER cells ,CARDIAC hypertrophy ,HEART cells ,HEART failure ,CARDIAC pacing - Abstract
New Findings: What is the central question of this study?We questioned whether the disruption of invariant natural killer T (iNKT) cells exacerbates left ventricular (LV) remodelling and heart failure after transverse aortic constriction in mice.What are the main findings and their importance?Pressure overload induced by transverse aortic constriction increased the infiltration of iNKT cells in mouse hearts. The disruption of iNKT cells exacerbated LV remodelling and hastened the transition from hypertrophy to heart failure, in association with the activation of mitogen‐activated protein kinase signalling. Activation of iNKT cells modulated the immunological balance in this process and played a protective role against LV remodelling and failure. Chronic inflammation is involved in the development of cardiac remodelling and heart failure (HF). Invariant natural killer T (iNKT) cells, a subset of T lymphocytes, have been shown to produce various cytokines and orchestrate tissue inflammation. The pathophysiological role of iNKT cells in HF caused by pressure overload has not been studied. In the present study, we investigated whether the disruption of iNKT cells affected this process in mice. Transverse aortic constriction (TAC) and a sham operation were performed in male C57BL/6J wild‐type (WT) and iNKT cell‐deficient Jα18 knockout (KO) mice. The infiltration of iNKT cells was increased after TAC. The disruption of iNKT cells exacerbated left ventricular (LV) remodelling and hastened the transition to HF after TAC. Histological examinations also revealed that the disruption of iNKT cells induced greater myocyte hypertrophy and a greater increase in interstitial fibrosis after TAC. The expressions of interleukin‐10 and tumour necrosis factor‐α mRNA and their ratio in the LV after TAC were decreased in the KO compared with WT mice, which might indicate that the disruption of iNKT cells leads to an imbalance between T‐helper type 1 and type 2 cytokines. The phosphorylation of extracellular signal‐regulated kinase was significantly increased in the KO mice. The disruption of iNKT cells exacerbated the development of cardiac remodelling and HF after TAC. The activation of iNKT cells might play a protective role against HF caused by pressure overload. Targeting the activation of iNKT cells might thus be a promising candidate as a new therapeutic strategy for HF. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
41. The enhanced immunopharmacology of VIB4920, a novel Tn3 fusion protein and CD40L antagonist, and assessment of its safety profile in cynomolgus monkeys.
- Author
-
Nicholson, Simone M., Casey, Kerry A., Gunsior, Michele, Drabic, Stacey, Iverson, William, Cook, Halie, Scott, Stephen, O'Day, Terry, Karanth, Subramanya, Dixit, Rakesh, and Ryan, Patricia C.
- Subjects
KRA ,CHIMERIC proteins ,IMMUNOPHARMACOLOGY ,LYMPHOCYTE count ,THERAPEUTICS ,KILLER cells ,CYTOTOXIC T cells ,B cells ,ANIMAL experimentation ,AUTOIMMUNE diseases ,PRIMATES ,GLYCOPROTEINS - Abstract
Background and Purpose: Inhibition of the T- and B-cell interaction through the CD40/CD40 ligand (L) axis is a favourable approach for inflammatory disease treatment. Clinical studies of anti-CD40L molecules in autoimmune diseases have met challenges because of thromboembolic events and adverse haemostasis. VIB4920 (formerly MEDI4920) is a novel CD40L antagonist and Tn3 fusion protein designed to prevent adverse haemostasis and immunopharmacology. We evaluated the pharmacokinetics, activity and toxicity of VIB4920 in monkeys.Experimental Approach: Cynomolgus monkeys received i.v. or s.c. 5-300 mg·kg-1 VIB4920 or vehicle, once weekly for 1 month (Studies 1 and 2) or 28 weeks (Study 3). VIB4920 exposure and bioavailability were determined using pharmacokinetic analyses, and immune cell population changes via flow cytometry. Pharmacological activity was evaluated by measuring the animals' capacity to elicit an immune response to keyhole limpet haemocyanin (KLH) and tetanus toxoid (TT).Key Results: VIB4920 demonstrated linear pharmacokinetics at multiple doses. Lymphocyte, monocyte, cytotoxic T-cell and NK cell counts were not significantly different between treatment groups. B-cell counts reduced dose-dependently and the T-cell dependent antibody response to KLH was suppressed by VIB4920 dose-dependently. The recall response to TT was similar across treatment groups. No thromboembolic events or symptoms of immune system dysfunctionality were observed.Conclusions and Implications: VIB4920 demonstrated an acceptable safety profile in monkeys. VIB4920 showed favourable pharmacokinetics, dose-dependent inhibition of a neoantigen-specific immune response and no adverse effects on immune function following long-term use. Our data support the use of VIB4920 in clinical trials. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
42. Clinical trial of a humanized anti‐IL‐2/IL‐15 receptor β chain in HAM/TSP.
- Author
-
Enose‐Akahata, Yoshimi, Oh, Unsong, Ohayon, Joan, Billioux, Bridgette Jeanne, Massoud, Raya, Bryant, Bonita R., Vellucci, Ashley, Ngouth, Nyater, Cortese, Irene, Waldmann, Thomas A., and Jacobson, Steven
- Subjects
PARAPARESIS ,CYTOTOXIC T cells ,HTLV ,HAM ,CLINICAL trials - Abstract
Objective: Human T cell lymphotropic virus 1 (HTLV‐1)‐associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a chronic, progressive, neurological disease. Chronic activation of CD8+ T cells, as evidenced by increased spontaneous lymphoproliferation and HTLV‐1‐specific cytotoxic T cells, has been demonstrated in HAM/TSP patients. Since IL‐2 and IL‐15 stimulate memory CD8+ T cell activity, these cytokines have been implicated in the immunopathogenesis of HAM/TSP. In this phase I trial, we evaluated the safety, pharmacokinetics, and ability of Hu‐Mikβ1, a humanized monoclonal antibody directed toward the IL‐2/IL‐15 receptor β‐chain (IL‐2/IL‐15Rβ: CD122), to saturate CD122 and regulate abnormal immune responses in patients with HAM/TSP by inhibition of IL‐15 action. Methods: Hu‐Mikβ1 was administered intravenously at doses of 0.5 mg/kg, 1.0 mg/kg, or 1.5 mg/kg in a total of nine HAM/TSP patients. Five doses of Hu‐Mikβ1 were administered at 3‐week intervals. The clinical response was evaluated using standardized scales. Viral and immunologic outcome measures were examined including HTLV‐1 proviral load, T cell phenotypic analysis and spontaneous lymphoproliferation in HAM/TSP patients. Results: There was no significant toxicity associated with Hu‐Mikβ1 administration in HAM/TSP patients. Saturation of CD122 by Hu‐Mikβ1 was achieved in five out of nine HAM/TSP patients. Administration of Hu‐Mikβ1 was associated with inhibition of aberrant CD8+ T cell function including spontaneous lymphoproliferation and degranulation and IFN‐γ expression, especially in HAM/TSP patients that achieved CD122 saturation. Interpretation: The treatment with Hu‐Mikβ1 had a number of immunological effects on HAM/TSP patients although no clinical efficacy was observed. We also did not see any dose‐related toxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
43. Comparative analysis of CDR3 regions in paired human αβ CD8 T cells.
- Author
-
Yu, Kun, Shi, Ji, Lu, Dan, and Yang, Qiong
- Subjects
T cell receptors ,T cells ,CYTOTOXIC T cells ,HUMAN T cells ,COMPARATIVE studies - Abstract
The majority of human CD8 cytotoxic T lymphocytes express αβ T‐cell receptors that recognize peptide–MHC class I complexes. Considerable attention has been devoted to TCR β repertoires, but study of TCR α chains has been limited. To gain a better understanding of the features of CDR3α and CDR3β in paired samples, we comprehensively analyzed 776 unique paired αβ TCR CDR3 regions in this study. We found that (I) the CDR3 length among paired αβ TCRs had a fairly narrow distribution due to random assortment of CDR3 length in alpha and beta chains; (II) nucleotide deletions among CDR3 regions were positively correlated with insertions in both α and β TCRs; (III) the CDR3 loops of both α and β chains contained an abundance of charged/polar residues and the CDR3 base regions contained a conserved motif; and (IV) the occurrence of Gly was CDR3 length‐ and position‐dependent in both chains, whereas the frequency of Ser at positions 106 and 107 was positively correlated with CDR3 length in TCR β. Overall, the amino acids in CDR3 loop regions were significantly different between TCR α and β, which suggests a distinct role for each chain in the recognition of antigen–MHC complexes. Here, we have provided detailed information on CDR3 in paired TCRs expressed on human CD8+ T cells and established the basis of a reference set for αβ TCR repertoires in healthy humans. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
44. PI3Kgamma Inhibitor Attenuates Immunosuppressive Effect of Poly(l-Glutamic Acid)-Combretastatin A4 Conjugate in Metastatic Breast Cancer.
- Author
-
Hanjiao Qin, Haiyang Yu, Jiyao Sheng, Dawei Zhang, Na Shen, Linlin Liu, Zhaohui Tang, and Xuesi Chen
- Subjects
METASTATIC breast cancer ,CYTOTOXIC T cells ,INDOLEAMINE 2,3-dioxygenase ,MACROPHAGES ,TUMOR growth ,THERAPEUTICS - Abstract
Vascular disrupting agents (VDAs) have great potential for cancer treatment. Poly(l-glutamic acid)-combretastatin A4 conjugate (PLG-CA4) is a novel class of VDAs. Though it has notable antitumor activity, it can induce host immune responses that promote tumor growth. Here, PLG-CA4 induces the polarization of tumor-associated macrophages (TAMs) toward the M2-like phenotype in 4T1 metastatic breast cancer (Control 30% vs PLG-CA4 53%; p < 0.05). Compared to the monotherapy of PLGCA4, inhibition of phosphoinositide 3-kinase gamma (PI3Kγ) attenuates the immunosuppressive effect of PLG-CA4 treatment by decreasing the number of M2-like TAMs (2.0 × 10
4 to 1.5 × 104 per tumor) and potential enhancement of cytotoxic T lymphocyte (3.0 × 104 to 5.7 × 104 per tumor). Importantly, PI3Kγ inhibitor synergizing with PLG-CA4 significantly extends the mean survival time from 52 days in monotherapy-treated mice to 61.8 days. Additionally, the combination of PLG-CA4 and PI3Kγ inhibitor improves the tumor therapeutic effect of NLG919, an inhibitor of immune checkpoint indoleamine 2,3-dioxygenase (IDO). As far as it is known, this is the first demonstrated study that VDAs induce the reshaping of macrophages to the M2-like phenotype. The findings also indicate a potential therapeutic strategy of the combination VDAs with an accurate immune modifier in the tumor to reverse the immune resistance. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
45. Early activation of CD95 is limited and localized to the cytotoxic synapse.
- Author
-
Sánchez, María Florencia, Murad, Fabronia, Gülcüler Balta, Gülce S., Martin‐Villalba, Ana, García‐Sáez, Ana J., and Carrer, Dolores C.
- Subjects
DEATH receptors ,CYTOTOXIC T cells ,KILLER cells ,APOPTOSIS ,IMMUNE system - Abstract
The cytotoxic synapse formed between cytotoxic T lymphocytes or natural killer cells expressing CD95L and target cells with CD95 on their surface is a key pathway for apoptosis induction by the immune system. Despite similarities with the immune synapse in antigen presenting cells, little is known about the role of the spatiotemporal organization of agonistic proteins/receptor interactions for CD95 signaling. Here, we have developed an artificial cytotoxic synapse to examine how mobility and geometry of an anti‐CD95 agonistic antibody affect receptor aggregation and mobility, ie the first step of receptor activation. By measuring the distribution, diffusion coefficient, and fraction of immobile CD95 receptor in living cells, we show that at short times, the initial activation of CD95 occurs locally and is limited to the contact region of the cytotoxic synapse. This anisotropic activation of apoptotic signaling supports a role for confined interactions on the efficiency of signal transduction that may have implications for biomedical applications of extrinsic apoptosis induction. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
46. A calcium optimum for cytotoxic T lymphocyte and natural killer cell cytotoxicity.
- Author
-
Zhou, Xiao, Friedmann, Kim S., Lyrmann, Hélène, Zhou, Yan, Schoppmeyer, Rouven, Knörck, Arne, Mang, Sebastian, Hoxha, Cora, Angenendt, Adrian, Backes, Christian S., Mangerich, Carmen, Zhao, Renping, Schwär, Gertrud, Hässig, Carmen, Lis, Annette, Qu, Bin, Kummerow, Carsten, Schwarz, Eva C., Hoth, Markus, and Cappello, Sabrina
- Subjects
CELL-mediated cytotoxicity ,CYTOTOXIC T cells ,CALCIUM metabolism ,CANCER prevention ,SMALL interfering RNA - Abstract
Key points: Cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells are required to eliminate cancer cells. We analysed the Ca
2+ dependence of CTL and NK cell cytotoxicity and found that in particular CTLs have a very low optimum of [Ca2+ ]i (between 122 and 334 n m) and [Ca2+ ]o (between 23 and 625 μ m) for efficient cancer cell elimination, well below blood plasma Ca2+ levels. As predicted from these results, partial down‐regulation of the Ca2+ channel Orai1 in CTLs paradoxically increases perforin‐dependent cancer cell killing. Lytic granule release at the immune synapse between CTLs and cancer cells has a Ca2+ optimum compatible with this low Ca2+ optimum for efficient cancer cell killing, whereas the Ca2+ optimum for CTL migration is slightly higher and proliferation increases monotonously with increasing [Ca2+ ]o . We propose that a partial inhibition of Ca2+ signals by specific Orai1 blockers at submaximal concentrations could contribute to tumour elimination. Abstract: Cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells are required to protect the human body against cancer. Ca2+ is a key metabolic factor for lymphocyte function and cancer homeostasis. We analysed the Ca2+ dependence of CTL and NK cell cytotoxicity against cancer cells and found that CTLs have a bell‐shaped Ca2+ dependence with an optimum for cancer cell elimination at rather low [Ca2+ ]o (23–625 μ m) and [Ca2+ ]i (122–334 n m). This finding predicts that a partial inhibition of Orai1 should increase (rather than decrease) cytotoxicity of CTLs at [Ca2+ ]o higher than 625 μ m. We tested this hypothesis in CTLs and indeed found that partial down‐regulation of Orai1 by siRNA increases the efficiency of cancer cell killing. We found two mechanisms that may account for the Ca2+ optimum of cancer cell killing: (1) migration velocity and persistence have a moderate optimum between 500 and 1000 μ m [Ca2+ ]o in CTLs, and (2) lytic granule release at the immune synapse between CTLs and cancer cells is increased at 146 μ m compared to 3 or 800 μ m, compatible with the Ca2+ optimum for cancer cell killing. It has been demonstrated in many cancer cell types that Orai1‐dependent Ca2+ signals enhance proliferation. We propose that a decrease of [Ca2+ ]o or partial inhibition of Orai1 activity by selective blockers in the tumour microenvironment could efficiently reduce cancer growth by simultaneously increasing CTL and NK cell cytotoxicity and decreasing cancer cell proliferation. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
47. Development of an epitope panel for consistent identification of antigen-specific T-cells in humans.
- Author
-
Fløe, Andreas, Løppke, Caroline, Hilberg, Ole, Wejse, Christian, Brix, Liselotte, and Jacobsen, Kivin
- Subjects
EPITOPES ,CYTOTOXIC T cells ,VIRAL disease treatment ,CANCER immunology ,MYCOBACTERIUM tuberculosis - Abstract
We aimed to establish a panel of MHC-peptide multimers suitable as a positive control in the detection of HLA A*0201 restricted antigen specific T cells ( ASTC) by flow cytometry. MHC Dextramers were loaded with HLA A*0201 binding peptides from viral antigens and melanoma targets identified from a literature search and in silico prediction. Peripheral blood mononuclear cells ( PBMC) from healthy donors were analysed with the MHC Dextramers using flow cytometry. The best performing epitopes were tested on PBMC from patients undergoing testing for Mycobacterium tuberculosis infection to assess the coverage of this epitope panel. Of 21 candidate epitopes, ASTC could be detected against 12 (57·1%) in at least one of 18 healthy blood donors. Reactivity to two or more epitopes was seen in 17 of the 18 donors (94·4%). We selected the six best-performing epitopes and demonstrated a positive response in 42 (97·7%) of 43 patient samples (healthy, latent and active M. tuberculosis infection). The selected panel of six antigenic epitopes sufficed as a positive control in the detection of ASTC in HLA A*0201. Performance was robust in different stages of latent and active M. tuberculosis infection, indicating reliability also during infection. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
48. A role for the histone H2A deubiquitinase MYSM1 in maintenance of CD8+ T cells.
- Author
-
Förster, Michael, Boora, Rupinder K., Petrov, Jessica C., Fodil, Nassima, Albanese, Isabella, Kim, Jamie, Gros, Philippe, and Nijnik, Anastasia
- Subjects
HISTONES ,UBIQUITIN-conjugating enzymes ,CD8 antigen ,CYTOTOXIC T cells ,LABORATORY mice - Abstract
Several previous studies outlined the importance of the histone H2A deubiquitinase MYSM1 in the regulation of stem cell quiescence and haematopoiesis. In this study we investigated the role of MYSM1 in T-cell development. Using mouse models that allow conditional Mysm1 ablation at late stages of thymic development, we found that MYSM1 is intricately involved in the maintenance, activation and survival of CD8
+ T cells. Mysm1 ablation resulted in a twofold reduction in CD8+ T-cell numbers, and also led to a hyperactivated CD8+ T-cell state accompanied by impaired proliferation and increased pro-inflammatory cytokine production after ex vivo stimulation. These phenotypes coincided with an increased apoptosis and preferential up-regulation of p53 tumour suppressor protein in CD8+ T cells. Lastly, we examined a model of experimental cerebral malaria, in which pathology is critically dependent on CD8+ T cells. In the mice conditionally deleted for Mysm1 in the T-cell compartment, CD8+ T-cell numbers remained reduced following infection, both in the periphery and in the brain, and the mice displayed improved survival after parasite challenge. Collectively, our data identify MYSM1 as a novel factor for CD8+ T cells in the immune system, increasing our understanding of the role of histone H2A deubiquitinases in cytotoxic T-cell biology. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
49. The MICA-129 dimorphism affects NKG2D signaling and outcome of hematopoietic stem cell transplantation.
- Author
-
Isernhagen, Antje, Malzahn, Dörthe, Viktorova, Elena, Elsner, Leslie, Monecke, Sebastian, Bonin, Frederike, Kilisch, Markus, Wermuth, Janne Marieke, Walther, Neele, Balavarca, Yesilda, Stahl‐Hennig, Christiane, Engelke, Michael, Walter, Lutz, Bickeböller, Heike, Kube, Dieter, Wulf, Gerald, and Dressel, Ralf
- Abstract
The MHC class I chain-related molecule A (MICA) is a highly polymorphic ligand for the activating natural killer (NK)-cell receptor NKG2D. A single nucleotide polymorphism causes a valine to methionine exchange at position 129. Presence of a MICA-129Met allele in patients ( n = 452) undergoing hematopoietic stem cell transplantation (HSCT) increased the chance of overall survival (hazard ratio [HR] = 0.77, P = 0.0445) and reduced the risk to die due to acute graft-versus-host disease (aGVHD) (odds ratio [OR] = 0.57, P = 0.0400) although homozygous carriers had an increased risk to experience this complication (OR = 1.92, P = 0.0371). Overall survival of MICA-129Val/Val genotype carriers was improved when treated with anti-thymocyte globulin (HR = 0.54, P = 0.0166). Functionally, the MICA-129Met isoform was characterized by stronger NKG2D signaling, triggering more NK-cell cytotoxicity and interferon-γ release, and faster co-stimulation of CD8
+ T cells. The MICA-129Met variant also induced a faster and stronger down-regulation of NKG2D on NK and CD8+ T cells than the MICA-129Val isoform. The reduced cell surface expression of NKG2D in response to engagement by MICA-129Met variants appeared to reduce the severity of aGVHD. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
50. Net MHC stab - predicting stability of peptide- MHC-I complexes; impacts for cytotoxic T lymphocyte epitope discovery.
- Author
-
Jørgensen, Kasper W., Rasmussen, Michael, Buus, Søren, and Nielsen, Morten
- Subjects
MAJOR histocompatibility complex ,EPITOPES ,CYTOTOXIC T cells ,IMMUNE response ,IMMUNE system ,CELLULAR immunity - Abstract
Major histocompatibility complex class I ( MHC-I) molecules play an essential role in the cellular immune response, presenting peptides to cytotoxic T lymphocytes ( CTLs) allowing the immune system to scrutinize ongoing intracellular production of proteins. In the early 1990s, immunogenicity and stability of the peptide- MHC-I (pMHC-I) complex were shown to be correlated. At that time, measuring stability was cumbersome and time consuming and only small data sets were analysed. Here, we investigate this fairly unexplored area on a large scale compared with earlier studies. A recent small-scale study demonstrated that pMHC-I complex stability was a better correlate of CTL immunogenicity than peptide- MHC-I affinity. We here extended this study and analysed a total of 5509 distinct peptide stability measurements covering 10 different HLA class I molecules. Artificial neural networks were used to construct stability predictors capable of predicting the half-life of the p MHC-I complex. These predictors were shown to predict T-cell epitopes and MHC ligands from SYFPEITHI and IEDB to form significantly more stable MHC-I complexes compared with affinity-matched non-epitopes. Combining the stability predictions with a state-of-the-art affinity predictions NetMHCcons significantly improved the performance for identification of T-cell epitopes and ligands. For the HLA alleles included in the study, we could identify distinct sub-motifs that differentiate between stable and unstable peptide binders and demonstrate that anchor positions in the N-terminal of the binding motif (primarily P2 and P3) play a critical role for the formation of stable pMHC-I complexes. A webserver implementing the method is available at www.cbs.dtu.dk/services/NetMHCstab. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.